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Summary An open, prospective, observational study was performed to assess
efficacy and adverse-event profile of topiramate as add-on therapy in epilepsy.
Outpatient neurology clinics from 11 general hospitals in Greece participated in
the study. In total, 211 patients with treatment resistant partial-onset seizures who
met the inclusion criteria, were studied. After baseline evaluation, topiramate was
given at a target dose of 200 mg/day over a 1-month titration period. In the
subsequent maintenance period, the topiramate dose could be varied according to
the clinical results. Patients were followed for in total 6 months, with monthly visits
and regular physical, neurological and laboratory examinations. Seizure frequencies* Corresponding author. Tel.: +31 13 5837 289; fax: +31 13 5837 300.
E-mail address: jvoene@jacnl.jnj.com (J.C. Van Oene).
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Monotherapy with one antiepileptic drug (AED), and
even combination therapy with two or more AEDs
together, quite often fail to produce adequate sei-
zure relief in patients with epilepsy. New AEDs have
become available over the past decade, providing
new treatment options, and topiramate appears to
be one of the promising examples. Topiramate is
authorised for the adjuvant treatment of partial
onset seizures with or without secondary general-
isation, primary generalised tonic—clonic seizures
and seizures associated with Lennox—Gastaut syn-
drome. In comparison with other AEDs, it ranks
among the most efficacious as was shown in a
meta-analysis.1 The number of patients to be trea-
ted, in order to obtain at least 50% reduction in
seizure frequency, was between six and nine for
other new AEDs such as tiagabine, zonisamide,
lamotrigine and gabapentin, but was only three
for topiramate.2 Randomised placebo-controlled
studies3,4 showed that the topiramate dose required
to produce these effects, was in the range of 200—
400 mg/day. In recent studies, topiramate was also
found efficacious as monotherapy.5,6 A double-blind
randomised trial comparing topiramate (100 or
200 mg/day) with either carbamazepine or valpro-
ate, showed that topiramate was as effective
as these older AEDs.7 Consequently topiramate
received official approval for use as monotherapy
in most European countries.
Regarding everyday clinical practice, it is good to
keep inmind that published data on topiramate add-
on treatments were almost exclusively gathered in
randomised controlled studies. Such studies applied
fixed doses and predetermined treatment regimens
that are assigned to patients on the basis of a
randomisation schedule rather than taking the
patient’s personal needs into account.3,8—12 Clinical
practice on the other hand, focuses on the individual
patient and aims at optimising his or her personaltherapy. Considerable differences in drug suscept-
ibility are known to exist from patient to patient,
and pragmatic titration is the usual approach to
determine which dose balances best antiepileptic
efficacyandadverseeventprofile inaparticular case.
We decided to investigate the everyday use of
topiramate in adult epilepsy patients with therapy-
resistant partial onset seizures, selected as outpa-
tients of non-specialised neurology clinics of general
hospitals.Patients and methods
Patients
Male and female patients, 18 years of age and over,
were eligible if they had experienced at least four
partial-onset seizures with or without secondary
generalisation, according to the International Clas-
sification of Seizures,13 in the 2 months preceding
study entry. Patients had to be treated with one or
more AEDs during the immediate pre-trial period.
Female patients of childbearing potential had to use
acceptable contraceptive methods during the trial;
pregnant or breast-feeding women could not be
included. Patients were excluded if they had a
treatable cause of seizures, progressive neurologi-
cal disorder, or a history of generalised status epi-
lepticus in the past 3 months. Patients with a
medical or social state that would influence their
reliable participation, or who were unable to com-
plete the diary or take their medication (not even
with available help), were also excluded.
The study was conducted in accordance with the
principles of the Declaration of Helsinki. After
approval by the applicable Institutional Review
Board, written informed consent was obtained from
each patient prior to study entry or any study-
related procedures.decreased to 35—40% of baseline values following 3 months of treatment and
remained relatively constant thereafter. The average monthly seizure frequency
over the 6-month study period was 4.61, compared to 9.21 at baseline. The number
of responders (patients with at least 50% reduction in seizure frequency) followed a
similar pattern, i.e., increase during the first 3 months levelling off at a final 80—85%
response rate. Of those completing the study, 30% had been seizure-free for at least 3
months and 12% for 5 months. Topiramate was well tolerated, no deviations in
laboratory values were found. Adverse events appeared to occur less frequently,
and antiepileptic effects were more pronounced in this prospective open-label study
than in earlier reports from randomised controlled trials. The nature of the patient
population and the application of individualised dose optimisation are proposed as
contributing factors to explain the favourable results of this study.
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Figure 1 Topiramate dose distribution categorised per
50 or 100 mg/day dose intervals, at various points in time
after adding topiramate to the treatment regimen. Num-
bers of patients involved were 207, 189 and 178 at months
1, 3 and 6, respectively.Study design
A prospective, open-label study was set up in the
outpatient general neurology (not specialised in
epileptology) clinics of 11 general hospitals, in
Greece. Co-ordination and supervision of these
clinics was performed by specialised epilepsy cen-
tres which were involved in the conduct of the
trial. Patients were followed over 6 months of
topiramate therapy, i.e., a 1-month initial titra-
tion period and a subsequent 5-month mainte-
nance period. After obtaining informed consent,
data from the last 7 weeks under the existing
antiepileptic treatment were collected (baseline
period). Topiramate, given as morning and
evening doses, was added to the treatment regi-
men and was started at 50 mg/day. Titration was
performed with weekly dose increments of 50 mg/
day to reach the initial target dose of 200 mg/day
at the end of the titration period. During the
maintenance period, the dose of topiramate
could be increased or decreased according to
the investigator’s judgement. Patients were
followed with once monthly visits to the clinic.
Physical and neurological examinations were
performed each visit, laboratory examinations
(haematology and blood biochemistry) every 3
months. Patients used a diary to keep track of
their seizures. The study focussed on the effi-
cacy, safety and side effects of the various anti-
epileptic treatment regimens in combination with
topiramate.
Statistical methods
The primary intent-to-treat analysis included all
patients that entered the study (=‘All patients’), a
secondary analysis was performed on those
patients who completed the trial (=‘Completers’).
No major differences appeared to exist between
the results of these analyses, though the one
with all patients showed more fluctuations over
time, and had a larger standard deviation for a
number of parameters, than the one with only the
completers.
Statistical analyses were performed using S-plus.
Seizures during the 7-week baseline period were
arithmetically corrected for the longer observation
time to produce a baseline monthly (i.e., 4-week)
seizure rate. Most of the results were analysed with
simple descriptive statistics. Where applicable Wil-
coxon’s two-sample test, Chi-square test, ANOVA or
Student’s t-test were performed. The level of sig-
nificance was set at p < 0.05. In case of multiple
comparisons a correction according to Bonferoni
was applied.Results
Study population
The 11 participating centres enrolled 211 patients
altogether. Thirty-one patients (15%) could not be
evaluated at the final visit due to early discontinua-
tion (dropout). Reasons for early discontinuation
were: adverse events (16 patients), lost to follow
up (6), insufficient response/exacerbation (3), with-
drawal of informed consent (2), non-compliance (1),
asymptomatic/cured (1), and not specified (2).
Baseline characteristics were in accordance with
general expectations: mean age was 37.0 years
(S.D. 15.3; range 13—77), 49% of patients were
female, no systematic age difference was found
between male and female patients.
Topiramate dose
The target dose, set for the end of the initial titra-
tion period, was 200 mg/day. The average dose
reached at the end of this 1-month period appeared
to be 187 mg/day (S.D. = 73, range 50—600,
n = 208).
During the subsequent maintenance period, the
dose was further increased in 65% of patients while a
reduction of the dose occurred in less than 3% of
patients. Three months after the initial titration
period the topiramate dose had risen to a mean
of 285 mg/day (S.D. 107; n = 186; median 300 mg/
day). The dose remained at that level till the end of
the study, at month 6 a mean dose of 298 mg/day
was found (S.D. 112; n = 178; median 300 mg/day).
Fig. 1 depicts the percent of patients for the
doses used at 1, 3 and 6 months after initiation
of the topiramate treatment. At the end of the
study (month 6) 86.5% of patients were satisfactorily
treated with a dose between 200 and 400 mg/day
(88.9% at month 3). Dose figures remained more or
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Figure 2 Mean seizure frequency over the previous
month, assessed at the various monthly visits. Data are
given for all patients (n = 211) and for the completers
(n = 180). Symbols indicate statistical significance for the
completers’ graph (significance for the all patients graph
were similar) and refer to Wilcoxon’s test with Bonferoni
correction. yp < 0.001 vs. baseline.less stable between months 3 and 6, so it appears
that the optimal dose was generally achieved within
3 months.
Other AEDs
Of the included patients, 141 used one other AED, 49
used two other AEDs and 14 patients used three
other AEDs besides topiramate (seven patients were
eventually treated with topiramate monotherapy).
The most common AEDs in topiramate combination
therapy were carbamazepine (CBZ; 48 patients),
oxcarbazepine (OCB; 41), valproate (VPA; 30), and
phenytoin (PHE; 12). With patients using two other
AEDs, the combination VPA + CBZ (eight patients),
CBZ + lamotrigine (LTG; 9), and VPA + OCB (seven)
were the most common. No combination occurred
more than twice in the patients using three AEDs
together with topiramate.
Efficacy
Seizure frequency
Fig. 2 presents the number of monthly seizures over
the preceding month for each visit. During the first
months of treatment, the graph for all patients
differs from the one of the completers, which isTable 1 Monthly seizure frequencies at baseline, during the
topiramate.
Monthly seizure frequency All patients (N = 201)
Mean (S.D.) Change fro
Baseline 9.2 (19.3) —
3 months treatment 6.7 (35.8) 27% ( p <
6 months treatment 4.6 (19.6) 50% ( p <
p-values refer to the change in seizure frequency from baseline usmainly due to one patient who had a very high
seizure frequency before he discontinued partici-
pating in the trial. The completers’ graph, which is a
better reflection of treatment effects over time,
clearly indicates that seizure frequency dropped
from the very moment topiramate treatment was
installed. After the initial titration period the drop
in seizure frequency further progressed until it
levelled off after 2—3 months at a level of 33—
39% of baseline frequency.
Cumulative seizure frequencies over the first 3
months of topiramate therapy, and over the whole
study period, were calculated and compared with
baseline data (Table 1). The median monthly seizure
rate decreased from 4.0 at baseline to 1.3 over 3
months, and to 1.0 over 6 months treatment (results
not shown). Monthly seizure frequencies over 3 and
6 months were statistically significantly lower than
at baseline.
Response rate
Table 2 indicates the number of patients with a
50% reduction in seizure frequency (the respon-
ders) over the indicated treatment period. Adding
topiramate to the treatment regimen resulted in an
increasing number of responders over time which,
after fine-tuning the dosage, appeared to stabilise
at 83—85%, 4 months after start of treatment.
Seizure freedom
All patients experienced seizures during the 7-week
baseline period. During the course of the trial the
number of patients with a seizure-free month rose
gradually. Like the reduction in seizure frequency
and the number of responders, this variable levelled
off over time, i.e., to 51—55% of patients in the last
3 months of the study (Fig. 3).
Also, an analysis was made of the length of the
seizure-free period at the end of the trial. It
appeared that no patient had been seizure-free
from the very start of the titration, but 12% had
remained seizure-free during the whole mainte-
nance period (5 months), and almost 30% remained
seizure-free for at least 3 months.first 3 and after the full 6 months add-on treatment with
Completers (N = 174)
m baseline Mean (S.D.) Change from baseline
7.9 (14.7) —
0.001) 4.1 (11.2) 48% ( p < 0.001)
0.001) 3.5 (10.5) 56% ( p < 0.001)
ing Wilcoxon test (two-sided).
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Table 2 Number of responders (patients with at least
a 50% reduction in monthly seizure frequency as com-
pared to baseline) vs. total number of observations at
the various follow-up visits after start of the topira-
mate treatment.
Duration of treatment Percent responders
(number of observations)
All patients Completers
1 month (initial titration) 40.4 (198) 42.1 (171)
2 months 67.0 (194) 67.2 (174)
3 months 76.1 (184) 75.6 (172)
4 months 84.7 (177) 84.2 (171)
5 months 83.0 (176) 82.6 (172)
6 months (trial end) 82.6 (172) 82.6 (172)
Figure 3 Percent of patients reporting a seizure-free
month at the various visits after the start of topiramate
add-on treatment (completers, n = 180).Safety/tolerability
Overall, 107 subjects (51%) experienced at least one
adverse event (AE) during topiramate treatment.
AEs reported by2% of the patients are presented in
Table 3, along with the putative relation to theTable 3 Adverse events that were reported by more
than 2% of all patients (n = 211) and the number of
these adverse events that were believed to be related
or possibly related to the use of topiramate.
Adverse event Total
occurrence
(Possibly)
related
N % N %
Weight decrease 27 13 21 10
Somnolence 23 11 21 10
Paraesthesia 22 10 9 4
Insomnia 9 4 1 0
Emotional lability 9 4 1 0
Dizziness 8 4 7 3
Fatigue 7 3 4 2
Anxiety 7 3 2 1
Nervousness 7 3 4 2
Headache 6 3 6 3
Anorexia 6 3 5 2
Depression 6 3 5 2topiramate treatment as assessed by the investiga-
tor (‘possibly related’ and ‘related’were combined,
the remaining cases were assessed as ‘not related’).
Weight reduction was the most frequently men-
tioned AE (13% of patients, see Table 3) but five
of these patients explicitly mentioned that they did
not want to lower the topiramate dose because of
that event.
Two serious adverse events were reported in this
study. The first one, a case of pneumothorax, was
interpreted as not related to the use of topiramate.
The second one, status epilepticus, was ascribed to
the underlying disorder.
Abnormalities found during the physical exami-
nation at study entry either remained stable or
disappeared. The same holds for the abnormalities
at the initial neurological examination, but in one
patient, signs of cerebellar dysfunction, in another
one signs of extrapyramidal dysfunction, were later
found to have developed during the trial. The inves-
tigators did not attribute either of these cases to the
use of topiramate. No deviating haematological or
biochemical values were detected following lab
analyses.Discussion
This study was undertaken to collect and summarise
ongoing practical experience with topiramate and,
in doing so, to guide general neurologists who con-
sider adding this drug to an existing antiepileptic
treatment regimen. The study focused on the effi-
cacy and side effects in patients with partial-onset
seizures. Study centres were general neurology hos-
pital-based outpatient clinics, rather than specia-
lised epilepsy clinics, and were selected to best
mimic everyday clinical practice. Efficacy and
safety data were monitored on a monthly basis
for 6 months, so more often than can usually be
achieved in neurological practice.
Efficacy assessment basically relied on seizure
counts that were normalised to monthly (28-day)
seizure frequencies. Three efficacy variables were
derived from these counts. First, the change in
monthly seizure frequency as compared to the base-
line (no topiramate treatment) was assessed for
each visit on treatment. Second, the number of
patients with an at least 50% drop in their monthly
seizure frequency relative to baseline was calcu-
lated. This yielded the number and percentage of
therapy ‘responders’. Third, the number of seizure-
free patients was assessed at each visit and the
length of the seizure-free period at trial completion
was calculated retrospectively for each individual.
These three parameters all indicated that the
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moment that topiramate co-treatment was
installed. The antiepileptic effect rose during the
first months and became stable after 3 months of
topiramate treatment.
Dose adaptations may have played a significant
role in this effect. Topiramate had to be titrated to
an initial 200 mg/day target dose, after which the
dose could be further adjusted to the patient’s
need. In practice, however, up to 60% of patients
had not yet reached this dose after the 1-month
initial titration period (Fig. 1). Further dose incre-
ments during the second and third months of treat-
ment were of such extent that they might well
explain the continued regression in seizure counts.
No substantial dose changes were seen beyond the
first 3 months of treatment. At study completion,
89% of patients were using topiramate in the recom-
mended dose range (i.e., 200—400 mg/day).14 Mean
and median topiramate doses happened to be right
in the middle of this range (i.e., 298 and 300 mg/
day, respectively).
The mean number of monthly seizures stabilised
at 33—39% of baseline, while the monthly seizure
frequency over the first 3 months decreased to 52%
(mean) or 33% (median) of baseline values. Over the
full 6-month treatment period, monthly seizure rate
was even more reduced to 44% (mean) or 25% (med-
ian) of baseline. In a recent meta-analysis of six
double-blind, randomised, placebo-controlled stu-
dies, Peeters et al.15 found a reduction to 55—62%
(median) of baseline values depending on the dose
(200—800 mg/day) and duration (8—12 weeks main-
tenance after 3—8 weeks initial titration) of topir-
amate treatment. Our results compared well with
these data, showing an even more pronounced
effect of topiramate than the meta-analysis. A pos-
sible explanation for this could be that, in contrast
to these randomised controlled trials, our study
allowed titration to an individual optimal dose, thus
enabling patients to benefit better from the newly
added topiramate treatment. A potential difference
in patient selection, however, cannot be ruled out as
a contributing factor. The study outcome could then
be interpreted in that we might have included less
severe cases and/or patients who were less resistant
to the effect of antiepileptic medication than in the
randomised controlled studies.
The response rate to topiramate also compared
well with the one found in randomised controlled
studies with AED refractory patients.15,16 In our
study, the number of responders stabilised at around
80% while in the meta-analysis response to topira-
mate varied from 24 to 44% of patients using doses
from 200 to 600 mg/day.15 In a comprehensive
randomised, placebo-controlled study, Gubermanet al.16 found a 44% reduction in seizure frequency
and 45% of patients responding over a 12-week
evaluation period. During the last 4 weeks of the
latter study (maintenance phase) figures improved
to 53% seizure reduction and 58% responders. In our
study, mean monthly seizure frequency dropped
50% over a 6-month period and 67% over the last
4 weeks when 83% of patients were still treatment
responders.
Frommonth3onwards,thenumberofpatientswith
a seizure-free month stabilised at 50—55%, 30% of
patients remained seizure-free till the end of the
study. About 12.5% of patients were without any
seizures during the entire 5-monthmaintenance per-
iod. This data too comparedwell with the 5% seizure-
free patients in Reife’s pooled analysis.17 Our results
with respect to seizure reduction, number of respon-
ders, number of seizure-free patients, and duration
of seizure-free periods, all suggested that a neurolo-
gist who adds topiramate to the antiepileptic treat-
ment regimen, may expect better results than
those reported from randomised controlled studies.
Apparently, response rates are higher in routine
clinical practice than in the tertiary referral centres
that are usually involved in the performance of
randomised controlled studies. It is not clearwhether
this is due to patient selection, individual versus
randomised topiramate dosing, or other causes.
The number of patients who discontinued this
trial prematurely, was rather low (15%) as compared
to many published trials on the use of AEDs in adults
with partial onset seizures (e.g.,18—20). The number
of withdrawals due to adverse events (7%) was as
good as that reported from randomised controlled
trials, i.e., a dose-dependent withdrawal rate of 7—
16% (topiramate doses of 200—600 mg/day).15
Adverse events reported in our study were the
ones known for topiramate. Most of them were
reported as ‘mild’. Reports of dizziness, psychomo-
tor slowing, confusion and speech disorder were
rare and occurred less frequently than reported
before. Somnolence for instance, was reported con-
siderably less often (11%) than in the pooled analysis
(30%)15 or in the manufacturer’s data file (29%).14
Depression, emotional lability, insomnia and anxiety
were reported in our study at a low rate, but were
not mentioned in earlier publications.15,16 However,
this may very well be explained by the fact that
these publications listed only those AEs occurring in
over 10% of patients, whereas the cut-off in our
study was laid at 2%. This again suggested that a low
adverse event rate can be expected when topira-
mate is used in regular epilepsy patients and is
titrated to a dose that, based on individual needs,
balances adverse events with appropriate antiepi-
leptic efficacy.
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Topiramate, given as add-on therapy to patients
with refractory partial-onset seizures, can be
titrated individually to reach an optimal effect after
3 months. In everyday clinical practice its efficacy
with respect to seizure reduction, number of ther-
apy responders, number of seizure-free patients and
number of consecutive seizure-free months, is likely
to be better than would be expected from the data
of published, randomised controlled trials. Adverse
events occur less frequently than reported in litera-
ture, and cause therapy discontinuation only in a
minority of patients.Acknowledgements
The authors would like to thank Martin Uitendaal,
Ph.D., for his assistance in the preparation of the
manuscript. This study was financially supported by
Janssen-Cilag Greece.Appendix A
The following investigators participated in the
Topiramate Observational Study Group, Greece:
St. Balogiannis, Thessaloniki
St. Gatzonis, Athens
K. Garganis, Thessaloniki
G. Georgiadis, Thessaloniki
St. Giannakodimos, Athens
K. Giatas, Athens
A. Karlovasitou, Thessaloniki
Ar. Kazis, Thessaloniki
V. Kimiskidis, Thessaloniki
K. Michailidis, Thessaloniki
N. Michalis, Thessaloniki
J. Milonas, Thessaloniki
D. Mitsikostas, Athens
P. Polychronopoulos, Patras
N. Ramopoulos, Thessaloniki
E. Thodi, Trikala
N. Triantafillou, Athens
St. Tsounis, ThessalonikiReferences
1. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs:
a systematic review of their efficacy and tolerability. Br Med
J 1996;313:1169—74.2. Elferink AJA, Van Zwieten-Boot BJ. Analysis based on number
needed to treat shows differences between drugs studied. Br
Med J 1997;314:603.
3. Sharief M, Viteri C, Ben-Menachem E, Weber M, Reife R,
Pledger G, et al. Double-blind, placebo-controlled study of
topiramate in patients with refractory partial epilepsy. Epi-
lepsy Res 1996;25:217—24.
4. Sander JWAS. Practical aspects of the use of topiramate in
patients with epilepsy. Epilepsia 1997;38:556—8.
5. Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate mono-
therapy for partial onset seizures. Epilepsia 1997;38:294—
300.
6. Gilliam FG, Veloso F, Bomhof MAM, Gazda SK, Biton V, Ter
Bruggen JP, Neto W, Bailey C, Pledger G, Wu S-C, the Topir-
amate EPMN 104 Study Group. A dose-comparison trial of
topiramate as monotherapy in recently diagnosed partial
epilepsy. Neurology 2003;60:196—202.
7. Privitera MD, Brodie MJ, Mattison RH, Chadwick DW, Neto W,
Wang S, EPMN 105 Study Group. Topiramate, carbamazepine
and valproate monotherapy: double-blind comparison in
newly diagnosed epilepsy. Acta Neurol Scand 2003;107:
165—75.
8. Faught E,Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger
GW, et al. Topiramate placebo-controlled dose-ranging trial
in refractory partial epilepsy using 200-, 400- and 600-mg
daily dosages. Neurology 1996;46:1684—90.
9. Ben Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt
D, Reid S, et al. Double-blind, placebo-controlled trial of
topiramate as add-on therapy in patients with refractory
partial seizures. Epilepsia 1996;37:539—43.
10. Tassinari CA, Michelucci R, Chauvel P, Chodkiewicz J, Shorvon
S, Henriksen O, et al. Double-blind, placebo-controlled trial
of topiramate (600 mg daily) for the treatment of refractory
partial epilepsy. Epilepsia 1996;37:763—8.
11. Privitera M, Fincham R, Penry J, Reife R, Kramer L, Pledger G,
et al. Topiramate placebo-controlled dose-ranging trial in
refractory partial epilepsy using 600-, 800-, and 1000-mg
daily dosages. Neurology 1996;46:1678—83.
12. Rosenfeld W, Abou-Khalil B, Reife R, Hegadus R, Pledger G,
Topiramate YF/YG Study Group. Placebo controlled trial
of topiramate as adjunctive therapy to carbamazepine
or phenytoin for partial-onset epilepsy. Epilepsia
1996;37(Suppl 5):153.
13. International League Against Epilepsy. International classifi-
cation of epileptic seizures. Epilepsia 1981;22:489—501.
14. PRI. Topamax (topiramate) Epilepsy Product Monograph;
2000.
15. Peeters K, Adriaenssen I, Wapenaar R, Neto W, Pledger G. A
pooled analysis of adjunctive topiramate in refractory partial
epilepsy. Acta Neurol Scand 2003;108:9—15.
16. Guberman A, Neto W, Gassmann-Mayer C, the EPAJ-119 Study
Group. Low-dose topiramate in adults with treatment-resis-
tant partial-onset seizures. Acta Neurol Scand 2002;106:
183—9.
17. Reife R, Pledger G, Wu S-C. Topiramate as add-on therapy:
pooled analysis of randomized controlled trials in adults.
Epilepsia 2000;41(Suppl 1):S66—71.
18. Grant SM, Heel RC. Vigabatrin: a review of its pharmacody-
namic and pharmacokinetic properties, and therapeutic
potential in epilepsy and motor control. Drugs 1991;41:
889—926.
19. Sander JWAS, Trevisol-Bittencourt PC, Hart YM, Patsalos PN,
Shorvon SD. The efficacy and long-term tolerability of lamo-
trigine in the treatment of severe epilepsy. Epilepsy Res
1990;7:226—9.
20. UK Gabapentin Group. Gabapentin in partial epilepsy. Lancet
1990;335:114—7.
